Bioprocessing and engineering characterisation of T-cell therapy manufacture in an ambr® 250 bioreactor

The use of engineered CAR-T cells in clinical trials has been growing over the last years. The recent approval of Kymriah® (Novartis) and Yescarta® (KitePharma) made CAR-T cell treatments available to a broader public. However, despite the recent successes and significant improvements, there are different aspects that need to be further assessed in order to develop a reproducible, cost-effective manufacturing process for the production of personalized T-cell therapies. This requires an approach, which generates sufficient quantities of patient-specific cells at the appropriate quality required for clinical application, overcoming the challenge imposed by significantly different starting material. Please click Additional Files below to see the full abstract